SUBSCRIBE
SUBSCRIBE

Krystal Biotech

NEWS
Drug Development
Krystal Biotech Announces Positive Interim Results from Placebo-Controlled Phase 1/2 Clinical Trial of KB103
KB103 is Krystal’s first “off-the-shelf”, topical, gene therapy candidate to treat patients suffering from Dystrophic Epidermolysis Bullosa.
October 19, 2018
 · 
9 min read
3 Biotechs That Could be Taken Out This Quarter
Deals
Gene Therapy Firm Krystal Biotech Files for $35 Million IPO
August 22, 2017
 · 
2 min read
Load More
JOBS
IN THE PRESS
Press Releases
Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024
July 26, 2024
 · 
1 min read
Pharm Country
Krystal Biotech to Present at the American Thoracic Society 2024 International Conference
May 15, 2024
 · 
2 min read
Pharm Country
Krystal Biotech to Present at BofA Securities 2024 Health Care Conference
May 8, 2024
 · 
1 min read
Business
Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates
May 6, 2024
 · 
17 min read
Pharm Country
Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
May 2, 2024
 · 
1 min read
Business
Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024
April 26, 2024
 · 
1 min read
Drug Development
Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung
April 22, 2024
 · 
5 min read
Pharm Country
Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting
April 4, 2024
 · 
2 min read
Pharm Country
Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference
February 28, 2024
 · 
1 min read
Business
Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
February 26, 2024
 · 
20 min read
Load More